Icosavax Initiates Phase 1 Trial of IVX-A12 Against RSV and hMPV in Older Adults
04. Oktober 2022 16:05 ET
|
Icosavax, Inc.
- IVX-A12 is the first combination bivalent vaccine candidate against both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) to reach clinical stage - - Phase 1 topline interim...
Icosavax Reports Second Quarter 2022 Financial Results and Provides Corporate Update
15. August 2022 16:05 ET
|
Icosavax, Inc.
– Announced positive topline interim Phase 1/1b results for VLP vaccine candidate IVX-121 against respiratory syncytial virus (RSV) - – Icosavax plans to file an IND and initiate a Phase 1 trial...
Icosavax Announces Results from IVX-411 Drug Product Investigation and Outlines Additional Corporate Milestones
28. Juli 2022 16:05 ET
|
Icosavax, Inc.
- Antigen component of IVX-411 found to be unstable; issue specific to molecule, with no evidence of read-through to other Icosavax programs - - Now focused on a bivalent strategy for COVID-19...
Icosavax to Participate in the William Blair Biotech Focus Conference
06. Juli 2022 16:05 ET
|
Icosavax, Inc.
SEATTLE, July 06, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax Announces Positive Topline Interim Phase 1/1b Results for VLP Vaccine Candidate IVX-121 Against RSV
28. Juni 2022 16:05 ET
|
Icosavax, Inc.
- IVX-121 demonstrated robust immunologic response to RSV, with comparable Geometric Mean Titer (GMT) levels achieved at Day 28 in both young and older adult groups - - IVX-121 was generally well...
Icosavax to Participate in the Jefferies Healthcare Conference
01. Juni 2022 16:05 ET
|
Icosavax, Inc.
SEATTLE, June 01, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle platform technology to develop combination...
Icosavax Reports First Quarter 2022 Financial Results and Provides Corporate Update
16. Mai 2022 16:05 ET
|
Icosavax, Inc.
- Enrollment completed in older adults portion of Phase 1/1b trial of IVX-121, a virus like particle (VLP) vaccine candidate displaying the prefusion stabilized Respiratory Syncytial Virus (RSV) F...
Icosavax Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
30. März 2022 16:15 ET
|
Icosavax, Inc.
- Completed dosing in older adults portion of Phase 1/1b clinical trial for IVX-121, a VLP vaccine candidate displaying the prefusion stabilized Respiratory Syncytial Virus (RSV) F antigen - -...
Icosavax Announces Topline Interim Phase 1/2 Results for IVX-411 Against SARS-CoV-2
25. März 2022 08:00 ET
|
Icosavax, Inc.
- Immunologic response observed in both SARS-CoV-2 naive and previously vaccinated subjects, but lower than expected and inconsistent with known data on company’s platform and VLP technology;...
Icosavax to Participate in the Cowen 42nd Annual Health Care Conference
02. März 2022 08:00 ET
|
Icosavax, Inc.
SEATTLE, March 02, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...